title: High rate of indigenous bronchiolitis and palivuzumab.
authors.forename: J S
authors.initials: JS
authors.lastname: Whitehall
authors.forename: S
authors.initials: S
authors.lastname: Bolisetty
authors.forename: J P
authors.initials: JP
authors.lastname: Whitehall
authors.forename: F
authors.initials: F
authors.lastname: Francis
authors.forename: R
authors.initials: R
authors.lastname: Norton
authors.forename: S K
authors.initials: SK
authors.lastname: Patole
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D001315:Australia; D001990:Bronchiolitis, Viral / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007223:Infant; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy* / Q000453:epidemiology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab